Evidence map›Paper›PMID 19145587›Full record

ReviewDiabetes/metabolism research and reviews2009

The role of insulin-like growth factor-I and its binding proteins in glucose homeostasis and type 2 diabetes.

Swapnil N Rajpathak, Marc J Gunter, Judith Wylie-Rosett, Gloria Y F Ho, Robert C Kaplan, Radhika Muzumdar, Thomas E Rohan, Howard D Strickler

Registry-linked trialAbstract readReview
In one paragraph

Review in Diabetes/metabolism research and reviews, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03610412 (Effect of Cinnamomum Cassia as an Enhancer of the Insulin Response of the Insulin-Like Growth Factor-1 and Metabolic Control in Patients With Type 2 Diabetes Mellitus Treated With Metformin Without Glycemic Control), which is not on this map. Cited by 124 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 1 pooled it
10.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03610412 phase3completednot on this mapstarted 2019, after this paper: background citation

Effect of Cinnamomum Cassia as an Enhancer of the Insulin Response of the Insulin-Like Growth Factor-1 and Metabolic Control in Patients With Type 2 Diabetes Mellitus Treated With Metformin Without Glycemic Control

TypeinterventionalSponsorCoordinación de Investigación en Salud, MexicoRan2019 to 2021Enrolled28ConditionsDiabetes Mellitus, Type 2ArmsCinnamomum Cassia, Placebo (calcined magnesia)
3 · Its place in the literature

Who cites it

124 citing papers in PubMed, 1 synthesis or guideline pooled it, 260 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. The novel adipokine Placin regulates glucose homeostasis via insulin secretion and IGF1 receptor signaling.Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Review

64 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Swapnil N RajpathakDepartment of Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx NY 10461, USA.
Marc J Gunter
Judith Wylie-Rosett
Gloria Y F Ho
Robert C Kaplan
Radhika Muzumdar
Thomas E Rohan
Howard D Strickler
Albert Einstein College of Medicine · US

Funding

Stable Isotope and Metabolomics CoreP60DK020541 · NIDDK · YESHIVA UNIVERSITY · PI FLEISCHER, NORMAN S. · 1986 to 2014
$29.8M
NIDDK NIH HHS 1R01DK08792NIDDK NIH HHS P60 DK020541NIDDK NIH HHS P60DK20541
6 · The paper itself

Abstract

This review addresses the possible role of the insulin-like growth factor (IGF)-axis in normal glucose homoeostasis and in the etiopathogenesis of type 2 diabetes. IGF-I, a peptide hormone, shares amino acid sequence homology with insulin and has insulin-like activity; most notably, the promotion of glucose uptake by peripheral tissues. Type 2 diabetes as well as pre-diabetic states, including impaired fasting glucose and impaired glucose tolerance, are associated cross-sectionally with altered circulating levels of IGF-I and its binding proteins (IGFBPs). Administration of recombinant human IGF-I has been reported to improve insulin sensitivity in healthy individuals as well as in patients with insulin resistance and type 2 diabetes. Further, IGF-I may have beneficial effects on systemic inflammation, a risk factor for type 2 diabetes, and on pancreatic beta-cell mass and function. There is considerable inter-individual heterogeneity in endogenous levels of IGF-I and its binding proteins; however, the relationship between these variations and the risk of developing type 2 diabetes has not been extensively investigated. Large prospective studies are required to evaluate this association.

Indexed as

Blood GlucoseDiabetes Mellitus, Type 2HomeostasisHumansInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor ILipidsBlood GlucoseInsulin-Like Growth Factor Binding Protein 1Insulin-Like Growth Factor Binding ProteinsInsulin-Like Growth Factor ILipids

Identifiers

PMID19145587
PMCPMC4153414
OpenAlexW2043194719

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.